Matthew Keller
Stock Analyst at HC Wainwright & Co.
(2.31)
# 2,680
Out of 5,006 analysts
8
Total ratings
62.5%
Success rate
8.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $4.31 | +619.78% | 2 | Sep 30, 2025 | |
| FGEN FibroGen | Reiterates: Buy | $43 | $11.41 | +276.86% | 2 | Sep 24, 2025 | |
| IFRX InflaRx | Assumes: Buy | $6 | $1.59 | +277.38% | 1 | Sep 2, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $7.31 | +146.13% | 1 | Aug 26, 2025 | |
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $2.35 | +495.74% | 1 | Aug 15, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Buy | $6 | $4.49 | +33.78% | 1 | Aug 14, 2025 |
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $4.31
Upside: +619.78%
FibroGen
Sep 24, 2025
Reiterates: Buy
Price Target: $43
Current: $11.41
Upside: +276.86%
InflaRx
Sep 2, 2025
Assumes: Buy
Price Target: $6
Current: $1.59
Upside: +277.38%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $7.31
Upside: +146.13%
Phio Pharmaceuticals
Aug 15, 2025
Reiterates: Buy
Price Target: $14
Current: $2.35
Upside: +495.74%
Galectin Therapeutics
Aug 14, 2025
Reiterates: Buy
Price Target: $6
Current: $4.49
Upside: +33.78%